F11R and invasive breast carcinoma: In the context of invasive breast cancer, taking into consideration the larger data set, the association between clinicopathologic data and survival data analyzed by McSherry et al. [21], [24] and Murakami et al. [22], high JAM-A expression should be a negative prognostic factor of patient outcome.